Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Return on Equity data on record, last reported at 0.32% in Q4 2025.

  • For Q4 2025, Return on Equity rose 53.0% year-over-year to 0.32%; the TTM value through Dec 2025 reached 0.32%, up 53.0%, while the annual FY2025 figure was 0.41%, 53.0% up from the prior year.
  • Return on Equity reached 0.32% in Q4 2025 per APLS's latest filing, down from 0.16% in the prior quarter.
  • Across five years, Return on Equity topped out at 9.36% in Q2 2021 and bottomed at 4.46% in Q4 2021.
  • Average Return on Equity over 5 years is 0.26%, with a median of 0.72% recorded in 2022.
  • The widest YoY moves for Return on Equity: up 411bps in 2022, down -988bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 4.46% in 2021, then soared by 92bps to 0.35% in 2022, then crashed by -543bps to 2.25% in 2023, then skyrocketed by 62bps to 0.85% in 2024, then surged by 63bps to 0.32% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.32% in Q4 2025, 0.16% in Q3 2025, and 1.42% in Q2 2025.